Company: IOBT
Filing Date: 2025-05-23
Form Type: S-3
Source: 0001193125-25-125831
Chunk: 15

Company: IO Biotech, Inc.
Filing Date: 2025-05-23
Form: S-3
Chunk 15
---
 the number and percentage of shares of our common stock beneficially owned by the selling stockholders as of May 19, 2025,
taking into account the number of shares that may be offered under this prospectus and the number and percentage of our common stock beneficially owned by the selling stockholders assuming all of the shares offered under this prospectus are sold.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares of our common stock. Generally, a person “beneficially owns” shares of our common stock if the person
has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights within 60 days.

All information contained in the table below and the footnotes thereto is based upon information provided to us by the selling stockholders. The information
in the table below and the footnotes thereto regarding shares of our common stock to be beneficially owned after the offering under this prospectus assumes the sale of all shares of our common stock being offered by the selling stockholders under
this prospectus. The percentage of shares of our common stock owned is based on 65,880,914 shares of our common stock issued and outstanding as of May 19, 2025. Unless otherwise indicated in the footnotes to this table, we believe that the
selling stockholders have sole voting and investment power with respect to the shares of our common stock indicated as beneficially owned.

As used in
this prospectus, the term “selling stockholder” includes the selling stockholders named below and any donees, pledgees, transferees or other
successors-in-interest selling shares of our common stock received after the date of this prospectus from the selling stockholders as a gift, pledge, or other non-sale related transfer. Other than the Finance Contract, the Side Letter, the Warrant Issuance Agreement, and other related transactions, there are no other material relations between the selling stockholder and
the Company.

The number of shares in the column “Maximum Number of Shares of Common Stock Offered” represents all of the shares of our common
stock that the selling stockholders may offer under this prospectus. The columns captioned “Ownership After Offering” assume the sale of all of the shares of our common stock offered by the selling stockholders under this prospectus and
that the selling stockholder does not acquire any additional shares of our common stock before the